Affordable Access

deepdyve-link
Publisher Website

Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1

Authors
  • Shi, Zhaopeng1
  • Gan, Guifang1
  • Xu, Xiang1
  • Zhang, Jieying1
  • Yuan, Yuan1
  • Bi, Bo1
  • Gao, Xianfu2
  • Xu, Pengfei3
  • Zeng, Wenbin3
  • Li, Jixi4
  • Ye, Youqiong1
  • Zhou, Aiwu1
  • Zhang, Naixia5
  • Liu, Wen6
  • Lin, Shuhai6
  • Mi, Jun1, 1
  • 1 Shanghai Jiao Tong University School of Medicine,
  • 2 Shanghai Profleader Biotech Co., Ltd, Shanghai, China
  • 3 Central South University,
  • 4 Fudan University,
  • 5 Chinese Academy of Sciences,
  • 6 Xiamen University,
Type
Published Article
Journal
Journal of Hematology & Oncology
Publisher
Springer Science and Business Media LLC
Publication Date
Sep 25, 2021
Volume
14
Identifiers
DOI: 10.1186/s13045-021-01165-4
PMID: 34563230
PMCID: PMC8465765
Source
PubMed Central
Keywords
Disciplines
  • Letter to the Editor
License
Unknown

Abstract

The 3-hydroxyanthranilic acid (3-HAA), a derivative of kynurenine, was reported to suppress tumor growth. However, the function of 3-HAA largely remains unclear. Here, we report that 3-hydroxyanthranilic acid (3-HAA) is lower in tumor cells, while adding exogenous 3-HAA induces apoptosis in hepatocellular carcinoma by binding YY1. This 3-HAA binding of YY1 leads to phosphorylation of YY1 at the Thr 398 by PKCζ, concomitantly enhances YY1 chromatin binding activity to increase expression of target genes. These findings demonstrate that 3-HAA is a ligand of YY1, suggesting it is a promising therapeutic candidate for HCC. Supplementary Information The online version contains supplementary material available at 10.1186/s13045-021-01165-4.

Report this publication

Statistics

Seen <100 times